<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605708</url>
  </required_header>
  <id_info>
    <org_study_id>R846-AD-1105</org_study_id>
    <nct_id>NCT01605708</nct_id>
  </id_info>
  <brief_title>Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending Dose Study of the Clinical Activity, Safety, Tolerability and Pharmacokinetics of a Single IV Dose of REGN846 in Refractory Moderate-to-Severe Pruritus in Adult Patients With Moderate-to-Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical activity on refractory moderate-to-severe&#xD;
      pruritus of a single intravenous (IV) dose of REGN846 in adult patients with&#xD;
      moderate-to-severe atopic dermatitis (AD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Activity</measure>
    <time_frame>Week 2</time_frame>
    <description>To assess the clinical activity on refractory moderate-to-severe pruritus of a single intravenous (IV) dose of REGN846 in adult patients with moderate-to-severe AD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Activity</measure>
    <time_frame>Week 4</time_frame>
    <description>To assess the clinical activity on refractory moderate-to-severe pruritus of a single intravenous (IV) dose of REGN846 in adult patients with moderate-to-severe AD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Activity</measure>
    <time_frame>Week 6</time_frame>
    <description>To assess the clinical activity on refractory moderate-to-severe pruritus of a single intravenous (IV) dose of REGN846 in adult patients with moderate-to-severe AD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability a single IV dose of REGN846</measure>
    <time_frame>Week 1 - Week 6</time_frame>
    <description>To assess the safety and tolerability of REGN846 in adult patients who have moderate-to-severe AD with refractory moderate-to-severe pruritus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile of a single IV dose of REGN846</measure>
    <time_frame>Week 1 - Week 6</time_frame>
    <description>To assess the PK profile of REGN846 in adult patients who have moderate-to-severe AD with refractory moderate-to-severe pruritus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of a single IV dose of REGN846</measure>
    <time_frame>Week 1 - Week 6</time_frame>
    <description>To assess the immunogenicity of REGN846 in adult patients who have moderate-to-severe AD with refractory moderate-to-severe pruritus.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pruritus</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN846</intervention_name>
    <description>Dose 1</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria include, but are not limited to the following:&#xD;
&#xD;
          1. Men and women between the ages of 18 and 65; women must be postmenopausal or&#xD;
             surgically sterile&#xD;
&#xD;
          2. Patients must have applied a stable dose of an additive-free, basic, bland emollient&#xD;
             twice daily for at least 7 days before the baseline visit&#xD;
&#xD;
          3. Chronic Atopic Dermatitis (AD)&#xD;
&#xD;
          4. Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive.&#xD;
&#xD;
          5. Refractory pruritus for â‰¥ 6 weeks before screening. Pruritus should be associated only&#xD;
             with AD and not with any other condition(s).&#xD;
&#xD;
          6. Itching associated with AD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria include, but are not limited to the following:&#xD;
&#xD;
          1. A history of listeriosis.&#xD;
&#xD;
          2. Presence of any 1 of the following tuberculosis (TB) criteria:&#xD;
&#xD;
               1. A history of active TB&#xD;
&#xD;
               2. A positive QuantiFERON TB test at the screening visit&#xD;
&#xD;
               3. Chest radiograph (posterior-anterior and lateral views) at screening or within 3&#xD;
                  months before the screening visit (radiology report must be available) with&#xD;
                  results consistent with prior TB infection (including but not limited to apical&#xD;
                  scarring, apical fibrosis, or multiple calcified granuloma). This does not&#xD;
                  include non-caseating granulomata.&#xD;
&#xD;
          3. Persistent chronic or active recurring infection requiring treatment with antibiotics,&#xD;
             antivirals, or antifungals within 4 weeks prior to the screening visit.&#xD;
&#xD;
          4. Any clinically significant physical abnormalities observed during the screening visit.&#xD;
&#xD;
          5. Diabetic, hypertensive, or any known atherosclerotic vascular disease.&#xD;
&#xD;
          6. Hospitalization for any reason within 60 days of the screening visit.&#xD;
&#xD;
          7. History of or positive human immunodeficiency virus (HIV) screen result at the&#xD;
             screening visit.&#xD;
&#xD;
          8. History of positive blood test for hepatitis B/hepatitis C or positive hepatitis&#xD;
             screen result at the screening visit.&#xD;
&#xD;
          9. Known sensitivity to doxycycline or tetracycline.&#xD;
&#xD;
         10. Known sensitivity to any of the components or excipients of the investigational&#xD;
             product formulation or history of hypersensitivity to any biologic agent.&#xD;
&#xD;
         11. Participation in any clinical research study evaluating another investigational drug&#xD;
             or therapy within 30 days or at least 5 half-lives (whichever is longer), of the&#xD;
             investigational drug prior to the screening visit.&#xD;
&#xD;
         12. Any medical or psychiatric condition that in the opinion of the investigator or&#xD;
             Regeneron, would place the patient at risk, interfere with participation in the study&#xD;
             or interfere with the interpretation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mahlow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osnabrueck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>October 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <disposition_first_submitted>September 27, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 27, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 28, 2013</disposition_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Itching</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

